Skip to content
type1.science
Phase 4Active, not recruitingNCT05757713

Teplizumab in pediatric stage-2 T1D

Phase 4/pediatric stage-2 teplizumab study, relevant after the expanding Tzield label and screening-to-treatment pathway.

Primary endpoints

  • Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)

Results so far

No results posted yet.